DB:SAZ

Stock Analysis Report

Executive Summary

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide.

Snowflake

Fundamentals

Reasonable growth potential with proven track record.


Similar Companies

Share Price & News

How has STADA Arzneimittel's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.05%

SAZ

2.7%

DE Pharmaceuticals

2.4%

DE Market


1 Year Return

1.0%

SAZ

-3.7%

DE Pharmaceuticals

2.3%

DE Market


Shareholder returns

SAZIndustryMarket
7 Day-0.05%2.7%2.4%
30 Day-0.1%0.2%-0.2%
90 Day2.2%10.7%0.6%
1 Year1.1%1.0%-0.4%-3.7%5.5%2.3%
3 Year158.1%151.7%-4.5%-12.5%18.9%8.6%
5 Year131.8%117.1%0.08%-12.3%44.8%25.1%

Price Volatility Vs. Market

How volatile is STADA Arzneimittel's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is STADA Arzneimittel undervalued compared to its fair value and its price relative to the market?

31.69x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Information is not available.

Information is not available.


Price To Earnings Ratio

Information is not available.

Information is not available.


Price to Earnings Growth Ratio

Information is not available.


Price to Book Ratio

Information is not available.


Next Steps

Future Growth

How is STADA Arzneimittel forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

21.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Information is not available.

Information is not available.

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Information is not available.

Information is not available.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has STADA Arzneimittel performed over the past 5 years?

0.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Information is not available.

Information is not available.

Information is not available.


Return on Equity

Information is not available.


Return on Assets

Information is not available.


Return on Capital Employed

Information is not available.


Next Steps

Financial Health

How is STADA Arzneimittel's financial position?


Financial Position Analysis

Information is not available.

Information is not available.


Debt to Equity History and Analysis

Information is not available.

Information is not available.

Information is not available.

Information is not available.


Balance Sheet

Information is not available.

Information is not available.


Next Steps

Dividend

What is STADA Arzneimittel's current dividend yield, its reliability and sustainability?

0.13%

Current Dividend Yield


Dividend Yield vs Market

company0.1%marketbottom25%1.4%markettop25%3.9%industryaverage2.8%forecastin3Years0.9%

Current dividend yield vs market & industry


Stability and Growth of Payments

Information is not available.

Information is not available.

Stable Dividend: SAZ is not paying a notable dividend for the German market, therefore no need to check if payments are stable.

Information is not available.


Current Payout to Shareholders

Information is not available.


Future Payout to Shareholders

Information is not available.


Next Steps

Management

What is the CEO of STADA Arzneimittel's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Peter Goldschmidt (54yo)

0.2yrs

Tenure

0

Mr. Peter Goldschmidt has been has been Chairman of the Executive Board & Chief Executive Officer at STADA Arzneimittel Aktiengesellschaft since September 1, 2018. He is an experienced generics manager an ...


Management Age and Tenure

1.3yrs

Average Tenure

53yo

Average Age

Information is not available.


Insider Trading

Information is not available.


Ownership Breakdown


Management Team

  • Mark Keatley (61yo)

    CFO & Member of Executive Board

    • Tenure: 1.2yrs
    • Compensation: €1.21m
  • Peter Goldschmidt (54yo)

    Chairman of the Executive Board & CEO

    • Tenure: 0.2yrs
  • Miguel Fernandez (53yo)

    CTO & Member of Executive Board

    • Tenure: 0.3yrs
  • Kay Reubelt

    Director of Investor Relations

    • Tenure: 2.2yrs
  • Sebastian Kramer-Bach (43yo)

    Executive Vice President of Corporate Communication

    • Tenure: 1.8yrs
  • Holger Pohlen (42yo)

    Director of Media Relations

    • Tenure: 1.4yrs

Board Members

  • Jürgen Böhm

    Member of Advisory Board

    • Tenure: 0yrs
  • Michael Siefke (51yo)

    Member of Supervisory Board

    • Tenure: 1.2yrs
  • Günter von Au (67yo)

    Chairman of Supervisory Board

    • Tenure: 1.2yrs
    • Compensation: €72.79k
  • Thomas Meyer (76yo)

    Chairman of Advisory Board

    • Tenure: 0yrs
  • Alfred Böhm

    Member of Advisory Board

    • Tenure: 0yrs
  • Gerd Berlin

    Member of Advisory Board

    • Tenure: 0yrs
  • Wolfgang Berger

    Member of Advisory Board

    • Tenure: 0yrs
  • Frank-R. Leu

    Deputy Chairman of Advisory Board

    • Tenure: 0yrs
  • Rika Aschenbrenner

    Member of Advisory Board

    • Tenure: 0yrs
  • Jens Steegers (38yo)

    Deputy Chairman of Supervisory Board

    • Tenure: 0yrs
    • Compensation: €167.62k

Company Information

STADA Arzneimittel Aktiengesellschaft's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: STADA Arzneimittel Aktiengesellschaft
  • Ticker: SAZ
  • Exchange: DB
  • Founded: 1895
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €5.082b
  • Shares outstanding: 62.26m
  • Website: https://www.stada.de

Number of Employees


Location

  • STADA Arzneimittel Aktiengesellschaft
  • Stadastrasse 2-18
  • Bad Vilbel
  • 61118
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STDA.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDFeb 1998
SAZDB (Deutsche Boerse AG)YesCommon SharesDEEURFeb 1998
SAZXTRA (XETRA Trading Platform)YesCommon SharesDEEURFeb 1998
0OM4LSE (London Stock Exchange)YesCommon SharesGBEURFeb 1998
SAZDBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURFeb 1998
SAZSWX (SIX Swiss Exchange)YesCommon SharesCHCHFFeb 1998
SAZWBAG (Wiener Boerse AG)YesCommon SharesATEURFeb 1998
STDA.YOTCPK (Pink Sheets LLC)ADRUSUSDDec 2008

Biography

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generic ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2018/11/13 18:08
End of Day Share Price2018/11/12 00:00
Earnings2018/06/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.